Claims for Patent: 8,980,839

Summary for Patent: 8,980,839

Title:	Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Abstract:	Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
Inventor(s):	Mitra; Ashim K. (Overland Park, KS), Weiss; Sidney L. (Randolph, NJ)
Assignee:	Ocular Technologies SARL (Epalinges, CH)
Application Number:	13/975,175
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,980,839
Patent Claims:	1. An aqueous ophthalmic solution , said solution comprising cyclosporine, a polyoxyl lipid or fatty acid and a polyalkoxylated alcohol, wherein said solution comprises mixed nanomicelles and wherein said solution does not include organic solvents. 2. The ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil. 3. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60 and HCO-80. 4. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises HCO-40. 5. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil and is present in an amount between 0.05-5% of the solution. 6. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil and is present in an amount between 0.5-1.5% of the solution. 7. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40 HCO-60, and HCO-80, and is present in an amount between 0.5-1.5% of the solution. 8. The aqueous ophthalmic solution of claim 1, wherein said polyalkoxylated alcohol is Octoxynol-40. 9. The aqueous ophthalmic solution of claim 1, wherein the polyalkoxylated alcohol is Octoxynol-40 and is present in an amount between 0.02 and 4% of the solution. 10. The aqueous ophthalmic solution of claim 1, wherein the polyalkoxylated alcohol is Octoxynol-40 and is present in an amount between 0.02 and 0.1% of the solution. 11. The aqueous ophthalmic solution of claim 1, wherein the cyclosporine is present in an amount between 0.05 and 5% of the solution. 12. The aqueous ophthalmic solution of claim 1, wherein the cyclosporine is present in an amount between 0.05 and 0.2% of the solution. 13. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil; and wherein said polyalkoxylated alcohol is Octoxynol-40. 14. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil and is present in an amount between 0.5-5% of the solution; and said polyalkoxylated alcohol is Octoxynol-40 and is present in an amount between 0.02 and 4% of the solution. 15. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil and is present in an amount between 0.5-1.5% of the solution; and said polyalkoxylated alcohol is Octoxynol-40 and is present in an amount between 0.02 and 0.1% of the solution. 16. The aqueous ophthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil and is present in an amount between 0.5-5% of the solution; said polyalkoxylated alcohol is Octoxynol-40 and is present in an amount between 0.02 and 4% of the solution; and the cyclosporine is present in an amount between 0.05 and 5% of the solution. 17. The aqueous opthalmic solution of claim 1, wherein said polyoxyl lipid comprises one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil and is present in an amount between 0.5-1.5% of the solution; and said polyalkoxylated alcohol is Octoxynol-40 and is present in an amount between 0.02 and 0.1% of the solution; and the cyclosporine is present in an amount between 0.05 and 0.2% of the solution. 18. The aqueous ophthalmic solution of claim 1, wherein said cyclosporin is entrapped in the core of mixed nanomicelles. 19. A method of treating or preventing an ocular disease or condition, said method comprising topically administering a solution of claim 1. 20. A method of treating or preventing an ocular disease or condition, said method comprising topically administering a solution of claim 17.